AstraZeneca plc (LON:AZN) announced a dividend on Friday, February 2nd, Upcoming.Co.Uk reports. Shareholders of record on Thursday, February 15th will be paid a dividend of GBX 133.60 ($1.85) per share by the biopharmaceutical company on Monday, March 19th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th. This is an increase from AstraZeneca’s previous dividend of $68.90. The official announcement can be viewed at this link.

Shares of AstraZeneca (LON:AZN) traded down GBX 8.50 ($0.12) during trading on Wednesday, reaching GBX 4,822 ($66.62). 752,141 shares of the company’s stock traded hands, compared to its average volume of 2,070,000. AstraZeneca has a 12-month low of GBX 4,260 ($58.86) and a 12-month high of GBX 5,520 ($76.26). The company has a market capitalization of $60,820.00 and a PE ratio of 2,819.88.

In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).

Several research firms have issued reports on AZN. Cfra set a GBX 4,800 ($66.32) price objective on AstraZeneca and gave the stock a “neutral” rating in a report on Friday, February 9th. Berenberg Bank boosted their price objective on AstraZeneca from GBX 5,800 ($80.13) to GBX 6,000 ($82.90) and gave the stock a “buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. set a GBX 5,500 ($75.99) price objective on AstraZeneca and gave the stock a “buy” rating in a report on Thursday, February 8th. UBS Group set a GBX 4,550 ($62.86) price objective on AstraZeneca and gave the stock a “neutral” rating in a report on Tuesday, February 6th. Finally, Kepler Capital Markets boosted their price objective on AstraZeneca from GBX 5,250 ($72.53) to GBX 5,300 ($73.22) and gave the stock a “buy” rating in a report on Tuesday, February 6th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 5,211.65 ($72.00).

WARNING: “AstraZeneca plc (AZN) Raises Dividend to GBX 133.60 Per Share” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/astrazeneca-plc-azn-raises-dividend-to-gbx-133-60-per-share.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Dividend History for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.